Press Release July 28, 2022

Larkspur Health Acquisition Corp. to Merge with ZyVersa Therapeutics

Alston & Bird client Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, has announced a definitive agreement to merge with ZyVersa Therapeutics Inc., a clinical stage specialty biopharmaceutical company.
 
The $108.92 million combination is expected to close during the fourth quarter of 2022, subject to approval by shareholders of Larkspur and shareholders of ZyVersa.
 
Representing Larkspur is an Alston & Bird team led by partners Matt Mamak and Stuart Rogers, senior associate Robyn Downing, and associates Misbah Mohiuddin and Siena Cornacchini (Corporate & Business Transactions) and associate Trenton Hafley (Litigation & Trial Practice).
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.